Nevro, Globus

Globus Medical strengthens SCS market position with $250m Nevro deal
GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Globus Medical to buy neurostim developer Nevro for $250M
Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. | With Globus paying $5.85 for each of Nevro’s outstanding shares,
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb.
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.
Globus Medical to buy California life sciences firm for $250M
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain for $250 million in cash. Audubon-based Globus (NYSE: GMED) will pay $5.85 per share for Nevro Corp. (NYSE: NVRO), representing a 17% premium to the company's closing stocking price on Wednesday.
Globus to buy Nevro for $250M
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale and orthopedic relationships.
Globus Medical to acquire Nevro for $5.85 per share
Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an
Globus Medical to acquire Nevro for $250 million
AUDUBON, Pa. - Globus Medical , Inc. (NYSE: NYSE:GMED), a prominent musculoskeletal solutions company with a market capitalization of $11.81 billion and an "GREAT" financial health rating according to InvestingPro,
Globus Medical to Acquire Nevro Corp. in Strategic $250 Million Deal
Globus Medical (NYSE: GMED) has announced a definitive agreement to acquire all shares of Nevro Corp. (NYSE: NVRO) in an all-cash transaction worth approximately
Globus Medical (GMED) Receives a Buy from Barclays
In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...
medtechdive4h
M&A and a separation take center stage in latest earnings season
BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...
Nasdaq4d
Globus Medical to Acquire Nevro Corp. in All-Cash Transaction Valued at $250 Million
Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...
Nevro upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
Hosted on MSN4d
Globus Medical reaffirms FY25 stand-alone EPS $3.40-$3.50, consensus $3.47
On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...
Jefferies maintains Buy on Globus Medical, target at $105
Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...
Nevro price target raised to $5.85 from $5 at Baird
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...